Capula Management’s Kyntra Bio KYNB Stock Holding History

Capula Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-941	Closed	-$439K	–	552
2023 Q1	$439K	Buy	+941	New	+$498K	0.01%	487

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capula Management's KYNB Position: Q2 2023 in Review

Capula Management sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 941 shares — an estimated $439K sold.

Capula Management first reported a position in KYNB in Q1 2023 and held it in 1 quarter. The position peaked at $439K in Q1 2023. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

Capula Management reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
Capula Management sold 941 Kyntra Bio shares in Q2 2023, an estimated $439K.
Capula Management first reported a position in Kyntra Bio in Q1 2023 and held it in 1 quarter.
Capula Management's Kyntra Bio position peaked at $439K in Q1 2023.
152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Capula Management's 13F filing for Q2 2023, filed 14 Aug 2023.